Analyst John Young CFA of Canaccord Genuity maintained a Buy rating on AngioDynamics, reducing the price target to $16.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
John Young CFA has given his Buy rating due to a combination of factors tied to AngioDynamics’ improving fundamentals and durable growth drivers. He notes that the company outperformed expectations in its latest quarter, raised full‑year guidance, and continues to post robust expansion in key Med‑Tech segments such as mechanical thrombectomy, Auryon, and NanoKnife, all supported by favorable reimbursement and rising procedure volumes.
At the same time, Young emphasizes that concerns over adjusted EBITDA are largely optical, as a one‑time milestone payment distorts quarter‑to‑quarter comparisons while underlying profitability remains positive. He also highlights that temporary gross margin and cash headwinds from inventory builds and the Costa Rica manufacturing transition are strategic, short‑term in nature, and manageable given the company’s balance sheet and tariff insulation, supporting a higher $16 price target and a Buy view on the shares.
Young CFA covers the Healthcare sector, focusing on stocks such as AngioDynamics, Staar Surgical, and Merit Medical Systems. According to TipRanks, Young CFA has an average return of -7.8% and a 32.65% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.